Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma

Takeshi Hara; Hisashi Tsurumi; Naoe Goto; Jun Ichi Kitagawa; Nobuhiro Kanemura; Takeshi Yoshikawa; Senji Kasahara; Hideko Goto; Kenji Fukuno; Toshiki Yamada; Michio Sawada; Ichiro Yasuda; Naoki Katsumura; Takeshi Takahashi; Tsuyoshi Takami; Hisataka Moriwaki

doi:10.1007/s00432-009-0637-x

Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma

Takeshi Hara, Hisashi Tsurumi^*, Naoe Goto, Jun Ichi Kitagawa, Nobuhiro Kanemura, Takeshi Yoshikawa, Senji Kasahara, Hideko Goto, Kenji Fukuno, Toshiki Yamada, Michio Sawada, Ichiro Yasuda, Naoki Katsumura, Takeshi Takahashi, Tsuyoshi Takami, Hisataka Moriwaki

^*Corresponding author for this work

Internal Medicine （3）

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Introduction: We previously described the effectiveness of the THP-COP regimen comprising cyclophosphamide, pirarubicin (tetrahydropyranyl adriamycin; THP), vincristine and prednisolone in patients with diffuse large B-cell lymphoma (DLBCL). The anthracycline drug THP was apparently less cardiotoxic than doxorubicin. However, that study was completed before rituximab was introduced into clinical practice. We conducted a phase II study to determine the effectiveness of a regimen incorporating rituximab (R-THP-COP) against DLBCL. Patients: Six to 8 courses of the regimen were administered every 2 weeks in 48 patients who were younger than 70 years. Results: The complete remission rate was 92%, the 3-year overall survival rate was 83% and 3-year progression free survival rate was 74%. No deaths were associated with the treatment regimen. Conclusion: We conclude that R-THP-COP regimen is very effective against DLBCL. The results of our study urge randomized trials of R-CHOP and R-THP-COP among patients with CD20+ DLBCL.

Original language	English
Pages (from-to)	65-70
Number of pages	6
Journal	Journal of Cancer Research and Clinical Oncology
Volume	136
Issue number	1
DOIs	https://doi.org/10.1007/s00432-009-0637-x
State	Published - 2010/01

Keywords

Non-Hodgkin's lymphoma
Pirarubicin
R-CHOP
R-THP-COP

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1007/s00432-009-0637-x

Cite this

Hara, T., Tsurumi, H., Goto, N., Kitagawa, J. I., Kanemura, N., Yoshikawa, T., Kasahara, S., Goto, H., Fukuno, K., Yamada, T., Sawada, M., Yasuda, I., Katsumura, N., Takahashi, T., Takami, T., & Moriwaki, H. (2010). Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma. Journal of Cancer Research and Clinical Oncology, 136(1), 65-70. https://doi.org/10.1007/s00432-009-0637-x

@article{555fa37f002f4d43a730b3adf4c079ba,

title = "Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma",

abstract = "Introduction: We previously described the effectiveness of the THP-COP regimen comprising cyclophosphamide, pirarubicin (tetrahydropyranyl adriamycin; THP), vincristine and prednisolone in patients with diffuse large B-cell lymphoma (DLBCL). The anthracycline drug THP was apparently less cardiotoxic than doxorubicin. However, that study was completed before rituximab was introduced into clinical practice. We conducted a phase II study to determine the effectiveness of a regimen incorporating rituximab (R-THP-COP) against DLBCL. Patients: Six to 8 courses of the regimen were administered every 2 weeks in 48 patients who were younger than 70 years. Results: The complete remission rate was 92%, the 3-year overall survival rate was 83% and 3-year progression free survival rate was 74%. No deaths were associated with the treatment regimen. Conclusion: We conclude that R-THP-COP regimen is very effective against DLBCL. The results of our study urge randomized trials of R-CHOP and R-THP-COP among patients with CD20+ DLBCL.",

keywords = "Non-Hodgkin's lymphoma, Pirarubicin, R-CHOP, R-THP-COP",

author = "Takeshi Hara and Hisashi Tsurumi and Naoe Goto and Kitagawa, {Jun Ichi} and Nobuhiro Kanemura and Takeshi Yoshikawa and Senji Kasahara and Hideko Goto and Kenji Fukuno and Toshiki Yamada and Michio Sawada and Ichiro Yasuda and Naoki Katsumura and Takeshi Takahashi and Tsuyoshi Takami and Hisataka Moriwaki",

year = "2010",

month = jan,

doi = "10.1007/s00432-009-0637-x",

language = "英語",

volume = "136",

pages = "65--70",

journal = "Journal of Cancer Research and Clinical Oncology",

issn = "0171-5216",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

Hara, T, Tsurumi, H, Goto, N, Kitagawa, JI, Kanemura, N, Yoshikawa, T, Kasahara, S, Goto, H, Fukuno, K, Yamada, T, Sawada, M, Yasuda, I, Katsumura, N, Takahashi, T, Takami, T & Moriwaki, H 2010, 'Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma', Journal of Cancer Research and Clinical Oncology, vol. 136, no. 1, pp. 65-70. https://doi.org/10.1007/s00432-009-0637-x

TY - JOUR

T1 - Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma

AU - Hara, Takeshi

AU - Tsurumi, Hisashi

AU - Goto, Naoe

AU - Kitagawa, Jun Ichi

AU - Kanemura, Nobuhiro

AU - Yoshikawa, Takeshi

AU - Kasahara, Senji

AU - Goto, Hideko

AU - Fukuno, Kenji

AU - Yamada, Toshiki

AU - Sawada, Michio

AU - Yasuda, Ichiro

AU - Katsumura, Naoki

AU - Takahashi, Takeshi

AU - Takami, Tsuyoshi

AU - Moriwaki, Hisataka

PY - 2010/1

Y1 - 2010/1

N2 - Introduction: We previously described the effectiveness of the THP-COP regimen comprising cyclophosphamide, pirarubicin (tetrahydropyranyl adriamycin; THP), vincristine and prednisolone in patients with diffuse large B-cell lymphoma (DLBCL). The anthracycline drug THP was apparently less cardiotoxic than doxorubicin. However, that study was completed before rituximab was introduced into clinical practice. We conducted a phase II study to determine the effectiveness of a regimen incorporating rituximab (R-THP-COP) against DLBCL. Patients: Six to 8 courses of the regimen were administered every 2 weeks in 48 patients who were younger than 70 years. Results: The complete remission rate was 92%, the 3-year overall survival rate was 83% and 3-year progression free survival rate was 74%. No deaths were associated with the treatment regimen. Conclusion: We conclude that R-THP-COP regimen is very effective against DLBCL. The results of our study urge randomized trials of R-CHOP and R-THP-COP among patients with CD20+ DLBCL.

AB - Introduction: We previously described the effectiveness of the THP-COP regimen comprising cyclophosphamide, pirarubicin (tetrahydropyranyl adriamycin; THP), vincristine and prednisolone in patients with diffuse large B-cell lymphoma (DLBCL). The anthracycline drug THP was apparently less cardiotoxic than doxorubicin. However, that study was completed before rituximab was introduced into clinical practice. We conducted a phase II study to determine the effectiveness of a regimen incorporating rituximab (R-THP-COP) against DLBCL. Patients: Six to 8 courses of the regimen were administered every 2 weeks in 48 patients who were younger than 70 years. Results: The complete remission rate was 92%, the 3-year overall survival rate was 83% and 3-year progression free survival rate was 74%. No deaths were associated with the treatment regimen. Conclusion: We conclude that R-THP-COP regimen is very effective against DLBCL. The results of our study urge randomized trials of R-CHOP and R-THP-COP among patients with CD20+ DLBCL.

KW - Non-Hodgkin's lymphoma

KW - Pirarubicin

KW - R-CHOP

KW - R-THP-COP

UR - http://www.scopus.com/inward/record.url?scp=71449091635&partnerID=8YFLogxK

U2 - 10.1007/s00432-009-0637-x

DO - 10.1007/s00432-009-0637-x

M3 - 学術論文

C2 - 19590893

AN - SCOPUS:71449091635

SN - 0171-5216

VL - 136

SP - 65

EP - 70

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

IS - 1

ER -

Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this